Laura Arnaldo

Ms. Laura Arnaldo

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AUAintzane Urbizu
Aintzane Urbizu
LALaura Arnaldo
Laura Arnaldo
KBKatrin Beyer
Katrin Beyer
The use of saliva as a biomarker source has advantages over other biofluids and imaging techniques, and miRNAs are ideal biomarker candidates. They are involved in numerous cellular processes, and their altered expression suggests that miRNAs play a crucial regulatory role in disease development. We wanted to find an easily reproducible and executable miRNA-obtaining methodology suitable for quantification. Three commercial miRNA extraction kits (mirVana, Nucleospin and miRNeasy) and three saliva collectors (50 mL tubes, Salimetrics and Oragene) were tested. Several features, including RNA quality and technical parameters, were evaluated. The expression of five synthetic spike-in controls and seven saliva-miRNAs was analyzed independently and grouped by the collectors and the extraction kits. The combination of Oragene and miRNeasy assured the most sensitive detection of all seven saliva miRNAs. Testing different combinations of saliva collectors and RNA purification kits permitted the establishment of combinations for different uses. The results of our study highlight that optimization of resources for biomarker studies is possible after careful planning of each study.

Verified
Journal Article
Open access
PDF file
Laura Marsal GarcíaLaura Marsal García
Laura Marsal García
AUAintzane Urbizu
Aintzane Urbizu
LALaura Arnaldo
Laura Arnaldo
JCJaume Campdelacreu
Jaume Campdelacreu
DVDolores Vilas
Dolores Vilas
KBKatrin Beyer
Katrin Beyer
Lewy body diseases (LBD) including dementia with Lewy bodies (DLB) and Parkinson disease (PD) are characterized by alpha-synuclein pathology. DLB is difficult to diagnose and peripheral biomarkers are urgently needed. Therefore, we analyzed the expression of five alpha-synuclein gene (SNCA) transcripts, SNCAtv1, SNCAtv2, SNCAtv3, SNCA126, and SNCA112, in 45 LBD and control temporal cortex samples and in the blood of 72 DLB, 59 PD, and 54 control subjects. The results revealed overexpression of SNCAtv1 and SNCA112 in DLB, and SNCAtv2 in PD temporal cortices. In DLB blood, diminution of all SNCA transcripts was observed. SNCAtv1 and SNCAtv2 were diminished in PD with disease onset before 70 years. SNCAtv3, driven by its own promoter, showed opposite expression in early DLB and PD, suggesting that its amount may be an early, DLB specific biomarker. Correlation between blood transcript levels and disease duration was positive in DLB and negative in PD, possibly reflecting differences in brain alpha-synuclein aggregation rates associated with differences in disease courses. In conclusion, SNCA transcripts showed a disease-specific increase in the brain and were diminished in blood of LBD patients. SNCAtv3 expression was decreased in early DLB and increased in early PD and could be a biomarker for early DLB diagnosis.

9 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LALaura Arnaldo
Laura Arnaldo
JMJorge Mena
Jorge Mena
MSMònica Serradell
Mònica Serradell
CGCarles Gaig
Carles Gaig
DCDavid Adamuz Comino
David Adamuz Comino
KBKatrin Beyer
Katrin Beyer
Individuals diagnosed with isolated REM sleep behavior disorder (IRBD) have a high risk of developing Lewy body disorders (LBD), mainly Parkinson’s disease (PD) or dementia with Lewy bodies (DLB). As we have previously identified seven platelet-derived miRNAs as potential biomarkers for DLB, in this pilot study we aimed to investigate whether specific expression changes of these miRNAs are also present in IRBD. RNA was obtained from platelets of individuals with IRBD (n = 29) and controls (n = 34), and miRNA levels were determined with a miRCURY LNA miRNA Custom PCR Panel. miRNA interactomes of deregulated miRNAs were determined, and mRNA quantification of miRNA target genes was carried out using real-time PCR and the ΔΔCt method. We found that the expression of hsa-miR- 139 - 5p (p = 0.010) and hsa-miR- 142 - 3p (p = 0.017) was diminished, while hsa-miR- 191 - 5p (p = 0.023) was increased in platelets of IRBD patients compared with controls. Interactome analysis of these miRNAs showed that hsa-miR- 142 - 3p regulates genes related to the structure and maintenance of the cytoskeleton. Of the 15 genes expressed in platelets, the expression of WASL, a gene involved in actin filament organization, was increased in platelets of IRBD patients. Additionally, WASL expression correlated inversely with hsa-miR- 142 - 3p expression. Since the interactomes of hsa-miR- 139 - 5p and hsa-miR- 191 - 5p play a role in several cancer types, their expression was not addressed. Changes in hsa-miR- 142 - 3p, hsa-miR- 139 - 5p, and hsa-miR- 191 - 5p expression were found in IRBD platelets and might represent early biomarkers for LBD involving cytoskeleton dysfunction. Increased expression of WASL could indicate that altered platelet activation occurs early during the development of LBD.

6 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LPLaura Pons
Laura Pons
LHLaura Hernández
Laura Hernández
AUAintzane Urbizu
Aintzane Urbizu
POPaula Osorio
Paula Osorio
PRPaula Rodríguez-Martínez
Paula Rodríguez-Martínez
PFPedro Luis Fernández
Pedro Luis Fernández
Neoadjuvant treatment (NAT) is one of the most widely used options for HER2+ and triple negative (TN) early breast cancer (BC). Since around half of the patients treated with NAT do not achieve a pathologically complete response (pCR), biomarkers to predict resistance are urgently needed. The correlation of clinicopathological factors with pCR was studied in 150 patients (HER2 = 81; TN = 69) and pre- and post-NAT differences in tumour biomarkers were compared. Low estrogen receptor (ER) expression, high tumour-infiltrating lymphocytes (TILs) and low cT-stage were associated with pCR in HER2+ tumours (p = 0.022; p = 0.032 and p = 0.005, respectively). Furthermore, ER expression was also associated with residual cancer burden (RCB; p = 0.046) in the HER2+ subtype. Similarly, pre-NAT, low progesterone receptor expression (PR; 1–10%) was associated with higher RCB (p < 0.001) in TN tumours. Only clinical and pathological T-stage (cpT-stage) had prognostic capacity in HER2+ tumours, whereas pre-NAT cpT-stage and post-NAT TILs had this capacity for the prognosis of TN tumours. We conclude that ER and PR expression may help predict response to NAT in HER2 and TN BC and should be taken into account in residual tumours. Also, changes observed in the phenotype after NAT suggest the need to reevaluate biomarkers in surviving residual tumour cells.

16 December 2025 in Brain Pathology
Verified
Journal Article
Open access
Laura Marsal GarcíaLaura Marsal García
Laura Marsal García
JMJorge Mena
Jorge Mena
CLCarol‐Ann Lao
Carol‐Ann Lao
DCDavid Adamuz Comino
David Adamuz Comino
LALaura Arnaldo
Laura Arnaldo
KBKatrin Beyer
Katrin Beyer
The 14‐3‐3 protein family plays a crucial role in cellular signaling and neuronal survival. Although 14‐3‐3 isoforms have been involved in the etiology of some neurodegenerative disorders, their role remains poorly understood in alpha‐synucleinopathies. In this study, we wanted to characterize 14‐3‐3 gene expression patterns in the brain and periphery of patients with Lewy body pathology (LBP). We analyzed messenger RNA (mRNA) expression of all seven 14‐3‐3 isotypes in the temporal cortex and caudate nucleus of brains with pure and common LBP, as well as in cerebrospinal fluid, peripheral blood, and platelets. Stratifin (SFN) protein expression was assessed by immunohistochemistry and enzyme‐linked immunosorbent assay. Effects of SFN overexpression on astrocyte activation were investigated in vitro. In the temporal cortex of LBP patients, six out of seven 14‐3‐3 genes were significantly downregulated, while SFN was markedly up‐regulated. SFN protein localized to neurofibrillary tangles in the parahippocampal region and reactive astrocytes in white matter. In vitro, SFN treatment induced biphasic changes in astrocytic glial fibrillary acidic protein expression, suggesting a role in glial activation. Peripheral analysis revealed no significant 14‐3‐3 mRNA changes in blood, but platelet expression patterns inversely correlated with brain tissue; six isoforms were up‐regulated, and SFN was strongly downregulated in dementia with Lewy bodies (DLB) platelets. Our findings revealed an important shift in 14‐3‐3 isotype expression in the temporal cortex of LBP patients, where SFN up‐regulation reflected its colocalization with tau pathology and astrocytic reactivity. The inverse expression profile in platelets in DLB highlights their potential as accessible biomarkers for molecular changes occurring in the brain.

Verified
Journal Article
Open access
PDF file
LALaura Arnaldo
Laura Arnaldo
JMJorge Mena
Jorge Mena
DCDavid Adamuz Comino
David Adamuz Comino
AMAlex Menéndez
Alex Menéndez
MSMònica Serradell
Mònica Serradell
KBKatrin Beyer
Katrin Beyer
Platelets are increasingly recognized as multifunctional cells with roles extending beyond hemostasis to immune regulation, inflammation, and neurodegeneration. Here, we performed RNA-Seq profiling of platelets from patients with idiopathic REM sleep behavior disorder (IRBD), dementia with Lewy bodies (DLB), Parkinson disease (PD), Alzheimer disease (AD), and healthy controls (CTRLs) to explore disease-specific transcriptomic signatures. Across all groups, the RNA class distribution was similar, dominated by mRNAs (78–80%) and long non-coding RNAs (lncRNAs; 15–16%). DLB platelets displayed a reduced proportion of lncRNAs, suggesting an impaired RNA regulation, whereas IRBD concentrated the highest number of disease-specific lncRNAs, half of which were Y-linked, consistent with the male predominance observed in alpha-synucleinopathies. Differential expression analysis (DEA) revealed extensive transcriptomic remodeling in IRBD and DLB, particularly affecting RNA processing, cytoskeletal organization, and platelet activation pathways, while PD and AD showed minimal changes. These findings suggest a progressive impairment of platelet activation and signaling across the DLB continuum, potentially mirroring neuronal dysfunction. The limited transcriptional deregulation in PD may reflect its pronounced biological heterogeneity, consistent with recent multidimensional disease models. Overall, our study highlights platelets as accessible indicators of early and disease-stage-specific molecular alterations in α-synucleinopathies.